Uphill Adcomm Battle For Telesta Bladder Cancer Agent?
This article was originally published in Scrip
Executive Summary
Telesta Therapeutics Inc. appears to be facing an uphill battle when it tries to convince an FDA advisory panel later this week to recommend approval of the company's experimental bladder cancer treatment, known as Mycobacterium phlei cell wall-nucleic acid complex (MCNA), a novel, microbiologically-derived, antineoplastic agent with immune-stimulant and direct anti-cancer activity.